Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

Rohit Loomba, Claude B Sirlin, Brandon Ang, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Linda Soaft, Jonathan Hooker, Yuko Kono, Archana Bhatt, Laura Hernandez, Phirum Nguyen, Mazen Noureddin, William Haufe, Catherine Hooker, Meng Yin, Richard Ehman, Grace Y Lin, Mark A Valasek, David A Brenner, Lisa Richards, San Diego Integrated NAFLD Research Consortium (SINC), Rohit Loomba, Claude B Sirlin, Brandon Ang, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Linda Soaft, Jonathan Hooker, Yuko Kono, Archana Bhatt, Laura Hernandez, Phirum Nguyen, Mazen Noureddin, William Haufe, Catherine Hooker, Meng Yin, Richard Ehman, Grace Y Lin, Mark A Valasek, David A Brenner, Lisa Richards, San Diego Integrated NAFLD Research Consortium (SINC)

Abstract

Ezetimibe inhibits intestinal cholesterol absorption and lowers low-density lipoprotein cholesterol. Uncontrolled studies have suggested that it reduces liver fat as estimated by ultrasound in nonalcoholic steatohepatitis (NASH). Therefore, we aimed to examine the efficacy of ezetimibe versus placebo in reducing liver fat by the magnetic resonance imaging-derived proton density-fat fraction (MRI-PDFF) and liver histology in patients with biopsy-proven NASH. In this randomized, double-blind, placebo-controlled trial, 50 patients with biopsy-proven NASH were randomized to either ezetimibe 10 mg orally daily or placebo for 24 weeks. The primary outcome was a change in liver fat as measured by MRI-PDFF in colocalized regions of interest within each of the nine liver segments. Novel assessment by two-dimensional and three-dimensional magnetic resonance elastography was also performed. Ezetimibe was not significantly better than placebo at reducing liver fat as measured by MRI-PDFF (mean difference between the ezetimibe and placebo arms -1.3%, P = 0.4). Compared to baseline, however, end-of-treatment MRI-PDFF was significantly lower in the ezetimibe arm (15%-11.6%, P < 0.016) but not in the placebo arm (18.5%-16.4%, P = 0.15). There were no significant differences in histologic response rates, serum alanine aminotransferase and aspartate aminotransferase levels, or longitudinal changes in two-dimensional and three-dimensional magnetic resonance elastography-derived liver stiffness between the ezetimibe and placebo arms. Compared to histologic nonresponders (25/35), histologic responders (10/35) had a significantly greater reduction in MRI-PDFF (-4.35 ± 4.9% versus -0.30 ± 4.1%, P < 0.019).

Conclusions: Ezetimibe did not significantly reduce liver fat in NASH. This trial demonstrates the application of colocalization of MRI-PDFF-derived fat maps and magnetic resonance elastography-derived stiffness maps of the liver before and after treatment to noninvasively assess treatment response in NASH.

© 2014 The Authors. HEPATOLOGY published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

Figures

Figure 1
Figure 1
(A) Individual patient data on liver fat content as assessed by MRI-PDFF before randomization and at the end of 24 weeks stratified by the treatment group assignment (ezetimibe-treated patients are to the left and shown by red lines, and placebo-treated patients are to the right and shown by blue lines). There was no significant difference in the changes in MRI-PDFF between the treatment groups (P = 0.483). (B) Percentage decline in liver fat relative to baseline by MRI-PDFF stratified by the treatment group assignment (ezetimibe-treated patients are to the left and shown by the red bar, and placebo-treated patients are to the right and shown by the blue bar). There was no significant difference in the changes in MRI-PDFF between the treatment groups (P = 0.266).
Figure 2
Figure 2
(A) Whole-liver fat mapping with MRI-PDFF for a single patient. MRI-PDFF measurements of liver segments 1, 2, 4a, 7, and 8 in the superior plane (upper panel) and of liver segments 3, 4b, 5, and 6 in the inferior plane (lower panel) are shown at weeks 0 (left column) and 24 (right column) for a patient. The fat fraction in a single liver segment is estimated by MRI-PDFF. Using nine ROIs, one in each segment, the calculated total liver fat fraction average at week 0 was 28%, and this decreased to 22% at week 24. MRI-PDFF data from all nine liver segments gives a fat map for the entire liver where longitudinal within-segment changes of liver fat can be appreciated. (B) MRS measured fat fraction in the same patient. MRS measurements from a 2 × 2 × 2 cm3 cube (voxel) within the right liver lobe of the same patient in which MRI-PDFF was performed are shown at week 0 (left column) and week 24 (right column). The corresponding MRS fat fraction at week 0 was 28.8%, and this decreased to 22% at week 24. (C) Liver stiffness measured by 2D and 3D MRE in the same patient. The 2D MRE was done at 60 Hz, and the 3D MRE was done at 40 Hz and 60 Hz. The MR shear wave elastograms obtained at week 0 are shown to the left, and those at week 24 are shown to the right. All three shear wave elastograms showed a decrease in the elasticity of the liver.

References

    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. et al.
    1. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131. et al.
    1. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121. et al.
    1. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. doi: .
    1. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.
    1. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–238. et al.
    1. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–951. et al.
    1. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913–924. et al.
    1. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971. et al.
    1. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685. et al.
    1. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307. et al.
    1. Zarrinpar A, Loomba R. The emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;36:909–921.
    1. Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology. 2013;57:81–92. et al.
    1. de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic fatty liver disease. J Lipids. 2012;2012:302847.
    1. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007;581:5664–5670. et al.
    1. Shiwa T, Kawanami Y, Yokoyama T, Moritani A, Hashimoto M, Gotoh T. The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD) Nihon Shokakibyo Gakkai Zasshi. 2011;108:1383–1392.
    1. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101–107. et al.
    1. Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012;56:922–932. et al.
    1. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930–1940. et al.
    1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. et al.
    1. Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol. 2008;6:1243–1248.
    1. Kuhn JP, Hernando D, Munoz del Rio A, Evert M, Kannengiesser S, Volzke H. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology. 2012;265:133–142. et al.
    1. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011;34:729–749.
    1. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease—MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22–29. et al.
    1. Reeder SB. Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. Hepatology. 2013;58:1877–1880.
    1. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013;268:411–419.
    1. Loomba R, Wolfson T, Ang B, Booker J, Behling C, Peterson M. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014;60:1920–1928. et al.
    1. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011;259:749–756.
    1. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37:544–555.
    1. Xanthakos SA, Podberesky DJ, Serai SD, Miles L, King EC, Balistreri WF. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr. 2014;164:186–188. et al.
    1. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007;5:1207–1213. et al.
    1. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B. Effect of weight loss on MRI estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 et al.. doi: .
    1. Oza N, Takahashi H, Eguchi Y, Kitajima Y, Kuwashiro T, Ishibashi E. Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease. Hepatol Res. 2014;44:812–817. et al.
    1. Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57:878–890. et al.
    1. Loomba R. Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014;12:1731–1732.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir